Neuland Laboratories Ltd (NEULANDLAB)
₹22,590.00
Mkt cap
₹29,073 Cr
P/E ratio
58.40
P/B
15.46
Div yield
0.15%
ROE
21.20%
ROCE
26.50%
EPS (TTM)
₹386.82
Book value
₹1,461
52W range
11,555–23,661
Sector
Healthcare
Price history
Previous close
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]
NSE NEULANDLABBSE 524558
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−4.53% from high₹22,590
₹11,555+95.50% from low₹23,661
Current
₹22,590.00
Prev close
₹22,640.00
Day
−0.22%
Price performance
1D
−0.22%
1W
−1.83%
1M
−1.16%
3M
+31.43%
6M
+76.82%
1Y
+68.59%
YTD
+47.88%
Financials
Revenue, profit & margin
P/E ratio
58.4×
NEULANDLAB is 72% above the sector median of 34.0×
NEULANDLAB58.4×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 | |
| Expenses | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 | |
| Operating Profit | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 | |
| OPM % | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% | |
| Other Income | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 | |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 | |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 | |
| Profit before tax | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 | |
| Tax % | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% | |
| Net Profit | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 | |
| EPS in Rs | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.42% · closed higher next day 21 of last 63
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 8 Feb '24◦ | 10 May '24◦ | 1 Aug '24◦ | 6 Nov '24 | 10 Feb '25◦ | 15 May '25 | 31 Jul '25◦ | 7 Nov '25◦ | 9 Feb '26◦ | 12 May '26◦ | 5 Aug '26◦ |
| Earnings day | +7.02% | +3.71% | −15.11% | +18.08% | −10.68% | −6.85% | −6.77% | −1.99% | +1.55% | −2.79% | −2.98% | +7.95% |
| +1 day | +14.02% | −1.14% | −13.56% | +16.84% | −13.11% | −7.00% | −5.41% | −1.49% | −3.61% | −5.04% | −1.90% | +14.53% |
| +5 days | +14.86% | +9.53% | −12.81% | +22.76% | −7.52% | −24.85% | −5.93% | −1.37% | −2.70% | −1.59% | −2.23% | +16.29% |
| +15 days | +16.41% | +11.35% | −14.36% | +26.85% | +5.37% | −19.31% | +9.87% | +1.85% | −7.01% | −8.02% | −0.84% | +17.74% |
| +30 days | +10.88% | −1.11% | +2.83% | +36.47% | −12.40% | −17.75% | +2.20% | +22.14% | −11.74% | −12.92% | +5.63% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 34 Per Share | 34.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Jun 202632.62%Promoter
Promoters32.62%0.01
FIIs21.08%0.62
DIIs16.52%0.68
Public29.79%1.29
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| NEULANDLAB | ₹22,660.00 | 58.41 | 29,073 | 0.15% | 148 | +962.37% | 642 | +119.16% | 26.47% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts77
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Credit Rating 25 Aug - CRISIL reaffirmed Neuland’s long-term rating A+/Positive and short-term rating A1 on August 25, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 23 AugDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 17 Aug - Malabar India Fund sold 2,72,634 Neuland shares; holding fell from 7.18% to 5.06%.Intimation Regarding Completion Of US FDA Inspection 14 Aug - US FDA inspected Unit 3 from Aug 10-14, 2026; issued Form 483 with one observation.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 10 Aug - Transcript of the Earnings Call conducted on August 5, 2026